<DOC>
	<DOCNO>NCT00504205</DOCNO>
	<brief_summary>RATIONALE : MP470 may stop growth cancer cell block enzymes need cell growth . PURPOSE : This clinical trial study side effect best dose MP470 treat patient unresectable metastatic refractory solid tumor , Hodgkin 's lymphoma , non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>MP470 Treating Patients With Unresectable Metastatic Solid Tumor Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate maximum tolerate dose ( MTD ) define safety profile multitargeted receptor tyrosine kinase inhibitor MP470 human . Secondary - Estimate therapeutic response rate patient receive MP470 . - Define human pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile MP470 capsule - Evaluate PK-PD relationship . OUTLINE : This multicenter study . Patients receive oral multitargeted receptor tyrosine kinase inhibitor MP470 maximum tolerate dose determine . Pharmacokinetic pharmacodynamic analysis carry determine change phosphorylation extracellular signal-regulated kinase ( ERK ) , Rad51 expression , number circulate tumor cell ( CTCs ) , tumor glucose metabolism measure 2- [ 18F ] fluoro-2-deoxyglucose positron emission tomography ( FDG-PET ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histological cytological diagnosis unresectable metastatic solidtumor cancer refractory standard therapy OR standard therapy exist Patients refractory lymphoma ( Hodgkin nonHodgkin ) also permit participate Exclusion criterion : Active CNS metastasis ( primary brain tumor permit ) PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status ≥ 70 % Hemoglobin ≥ 9 g/dL ANC ≥ 1.5 × 10^9/L Platelet count ≥ 100 × 10^9/L Total serum bilirubin ≤ 2 mg/dL AST ALT ≤ 2.5 × ULN ( upper limit normal clinical laboratory ) , ≤ 5 × ULN acceptable due hepatic metastasis Serum albumin ≥ 2 g/dL Serum creatinine ≤ 2 mg/dL LVEF ≥ 50 % ECHO No significant abnormality screen ECG ( e.g. , leave bundle branch block , 3rd degree AV block , acute myocardial infarction QTc interval &gt; 450 msec ) No history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia family history Long QT Syndrome ) Able swallow MP470 capsule Capable fast 6 hour Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month follow completion study treatment Exclusion criterion : Lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise patient 's safety , interfere absorption metabolism oral MP470 , put study outcome risk Any serious , uncontrolled active infection require systemic treatment History significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , and/or myocardial infarction PRIOR CONCURRENT THERAPY : Inclusion criterion : Recuperated prior surgical procedure include least 4 week rest since major surgery Exclusion criterion : Patient receive anticancer agent ( ) within past 3 week , include investigational agent , chemotherapy ( 6 week nitrosoureas mitomycin ) , immunotherapy , biologic , hormonal therapy luteinizing hormonereleasing hormone ( LHRH ) agonists Patient receive radiation therapy within past 4 week Patient grade 2 severe toxicity ( alopecia ) continue prior anticancer therapy Patient require treatment immunosuppressive agent corticosteroid stable dos least 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>